Investigating how certain proteins recognize and respond to DNA from pathogens
Official title: DNA Binding Dynamics and Oligomerization of Sensors of the PYHIN family in Pattern Recognition
Funded at University of California, Merced · NIH-11200534 · Data updated 2026-11-12
This study is looking at how certain proteins in your body recognize and respond to harmful germs, which could help us find new ways to treat autoimmune diseases and cancer by improving how your immune system reacts.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, Merced NIH-funded |
| Lab location | 1 site (Merced, United States) |
| Project start | June 10, 2025 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $414,682 |
| NIH project number | 1R15AI192356-01 |
| Project ID | NIH-11200534 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with autoimmune disorders or certain types of cancer that may be influenced by the AIM2 and IFI16 proteins.
✕Less likely to help
Patients with conditions unrelated to inflammation or the specific mechanisms of AIM2 and IFI16 may not benefit from this research.
What this research studies
This research focuses on understanding how specific proteins, known as pattern recognition receptors, detect DNA from harmful bacteria and viruses. By studying the binding dynamics and oligomerization of the AIM2 and IFI16 proteins, the research aims to uncover how these proteins trigger inflammatory responses that are crucial for the body's defense against infections. The approach involves analyzing the 3D structures of these proteins and their interactions, which could lead to new insights into their roles in autoimmune diseases and cancer treatment. Patients may benefit from the development of targeted therapies that modulate these inflammatory responses.
Why it matters
Potential benefit: If successful, this research could lead to new anti-inflammatory and anti-cancer therapies that improve patient outcomes.
How similar studies have gone: Previous research has shown promise in targeting similar pathways for therapeutic interventions, indicating potential for success in this area.
Where this research is happening
-
University of California, Merced
Merced, United States Active
Researchers
- Principal investigator: De Alba Bastarrechea, Eva — University of California, Merced
- Study coordinator: De Alba Bastarrechea, Eva
Related research
Other NIH-funded projects on the same topics.
-
HOME: Smart, compassionate AI helpers for aging at home
A research project is developing an AI-powered, multimodal system to help older adults stay safe and healthy at home while supporting busy caregivers.
-
How master 'pioneer' proteins read DNA and shape cell identity
This project looks at how special 'pioneer' proteins read DNA inside cells to guide development and how those processes relate to cancer and regenerative medicine.
-
Engineering vCCI to change how it binds chemokines
Researchers will study a viral protein called vCCI that can calm inflammation and explore how to tweak its binding to inflammation signals to potentially help conditions like arthritis and asthma.
-
How stem cells renew tissues and cancer development, using planarians
A scientist team at UC Merced studies how stem cells renew tissues and how DNA damage can lead to cancer, using a planarian model to understand early changes.
-
Understanding how blood vessels and endothelial cells help the thymus heal after intensive cancer therapy
This NIH grant explores how blood vessels and their lining cells help the thymus recover after chemotherapy, aiming to support better immune recovery in adults.
-
Understanding how enzyme shapes and movements control their activity
This grant explores how temperature-driven changes in enzyme shapes affect their activity, with the goal of finding hidden states that could help drug discovery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.